UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
May 10, 2017 08:00 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address...
UroGen Pharma Announces Pricing of Initial Public Offering
May 03, 2017 17:54 ET
|
UroGen Pharma
RA’ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of...
UroGen Pharma Welcomes New Board Member Kate Falberg
April 24, 2017 07:00 ET
|
UroGen Pharma
RA’ANANA, Israel, April 24, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address...
UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
April 03, 2017 08:00 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments...
UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma
December 12, 2016 07:00 ET
|
UroGen Pharma
RA’ANANA, Israel and NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company, today announced the acceptance of its Investigational...
UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
October 14, 2016 07:00 ET
|
UroGen Pharma
RAANANA, Israel, Oct. 14, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma (“UroGen”), a privately-held, clinical-stage biotechnology company, announced today that it has completed an agreement to...
UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting
May 05, 2016 08:30 ET
|
UroGen Pharma Ltd.
NEW YORK and RA’ANANA, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for...
UroGen Pharma Strengthens Board of Directors and Senior Management Team
February 09, 2016 08:00 ET
|
UroGen Pharma Ltd.
NEW YORK and RA’ANANA, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, Ltd. a clinical-stage biopharmaceutical company developing novel, locally-administered pharmaceutical solutions for...
UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline With Addition of TLR-7 Agonist Phase 2 Asset
January 13, 2016 08:00 ET
|
UroGen Pharma Ltd.
NEW YORK and RA'ANANA, Israel, Jan. 13, 2016 (GLOBE NEWSWIRE) -- UroGen Pharma, Ltd. (formerly known as TheraCoat), a clinical-stage biopharmaceutical company developing novel,...